SCHEMBL25925970

SCHEMBL25925970

CC(=O)c1ccccc1/N=N/c1ccc(N(C)C)c(/N=N/c2nc3ccccc3s2)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 4/20 0.47
MAPT P10636 7/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
KMT2A Q03164 4/20 0.41
MCL1 Q07820 3/20 0.41
CASP3 P42574 2/20 0.41
SENP7 Q9BQF6 2/20 0.41
SENP6 Q9GZR1 2/20 0.41
MEN1 O00255 3/20 0.40
TP53 P04637 3/20 0.38
TSHR P16473 2/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTPN11 Q06124 1/20 0.38
MAPK1 P28482 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25926003 0.79 INSR (0.45) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL28547027 0.74 INSR (0.62) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL8652864 0.72 INSR (0.59) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL29475610 0.72 INSR (0.59) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL8652866 0.72 INSR (0.59) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL16252394 0.71 INSR (0.66) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL25925767 0.68 MAPT (0.43) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL10781114 0.68 INSR (0.61) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL10781118 0.68 INSR (0.61) INSRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL25925972 0.67 MYC (0.34) MAPTNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE AR, MAPT, NR5A1 INSR 848/4885MAPT 2/4885SMN1; SMN2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.